Robeco Institutional Asset Management B.V. Sells 75,067 Shares of Hologic, Inc. (NASDAQ:HOLX)

Robeco Institutional Asset Management B.V. lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 47.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 84,580 shares of the medical equipment provider’s stock after selling 75,067 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Hologic were worth $5,225,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Norges Bank bought a new position in shares of Hologic during the 4th quarter worth about $133,414,000. Boston Partners increased its stake in Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after acquiring an additional 1,602,463 shares during the period. Champlain Investment Partners LLC acquired a new position in Hologic in the 4th quarter valued at approximately $79,291,000. Redwood Wealth Management Group LLC bought a new stake in shares of Hologic in the 1st quarter worth approximately $3,534,000. Finally, Northern Trust Corp lifted its position in shares of Hologic by 26.9% in the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider’s stock worth $226,898,000 after acquiring an additional 668,086 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Martin D. Madaus acquired 5,445 shares of the firm’s stock in a transaction on Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director directly owned 5,445 shares in the company, valued at $300,781.80. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 1.88% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HOLX. Citigroup cut their target price on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Morgan Stanley dropped their price objective on shares of Hologic from $77.00 to $65.00 and set an “equal weight” rating for the company in a research note on Monday, May 5th. Royal Bank Of Canada decreased their target price on shares of Hologic from $75.00 to $70.00 and set a “sector perform” rating on the stock in a research report on Friday, May 2nd. Wall Street Zen lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. Finally, Evercore ISI cut their price target on shares of Hologic from $65.00 to $62.00 and set an “in-line” rating for the company in a research note on Friday, May 2nd. Twelve research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $77.42.

Hologic Stock Performance

NASDAQ HOLX opened at $65.16 on Tuesday. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67. The company has a 50 day moving average of $60.17 and a 200-day moving average of $63.84. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. The firm has a market cap of $14.52 billion, a price-to-earnings ratio of 27.49, a PEG ratio of 2.38 and a beta of 0.55.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The business’s revenue was down 1.2% on a year-over-year basis. During the same period last year, the firm posted $1.03 EPS. On average, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.